Biogen (BIIB) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $232.65, -1.15% vs the prior close of $235.35.
- Volume 1.46M shares, 1.5x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
BIIB dips 1.1% to $232.65. Closed at $232.65, -1.15% vs the prior close of $235.35. Day range $232.46–$236.74, opened at $235.77.
BIIB daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — BIIB dips 1.1% to $232.65
- Closed at $232.65, -1.15% vs the prior close of $235.35. Day range $232.46–$236.74, opened at $235.77.
- Volume was 1.46M shares, 1.5x its 50-day average of 967.11K.
- Price is +5.9% vs its 50-day average ($219.71) and +17.6% vs its 200-day average ($197.83).
- 52-week range $138.00–$240.99; today's close sits at 92% of that range, 3.5% below the 52-week high.
Oct 15, 2026 — BIIB rises 1.1% to $235.35, a 52-week high
- Closed at $235.35, +1.08% vs the prior close of $232.83. Day range $235.22–$240.99, opened at $236.46.
- Volume was 1.57M shares, 1.6x its 50-day average of 953.13K.
- Price is +7.4% vs its 50-day average ($219.18) and +19.1% vs its 200-day average ($197.55).
- 52-week range $138.00–$240.99; today's close sits at 95% of that range, 2.3% below the 52-week high.
Oct 14, 2026 — BIIB rises 1.7% to $232.83, a 52-week high on 2.1x normal volume
- Closed at $232.83, +1.72% vs the prior close of $228.90. Day range $228.00–$234.20, opened at $228.99.
- Volume was 1.95M shares, 2.1x its 50-day average of 938.30K — unusually heavy trading.
- Price is +6.5% vs its 50-day average ($218.61) and +18.0% vs its 200-day average ($197.25).
- 52-week range $138.00–$238.24; today's close sits at 95% of that range, 2.3% below the 52-week high.
Oct 13, 2026 — BIIB ends flat (-0.2%) to $228.90
- Closed at $228.90, -0.22% vs the prior close of $229.41. Day range $226.71–$231.04, opened at $230.34.
- Volume was 1.05M shares, 1.1x its 50-day average of 936.13K.
- Price is +4.9% vs its 50-day average ($218.12) and +16.2% vs its 200-day average ($196.98).
- 52-week range $138.00–$238.24; today's close sits at 91% of that range, 3.9% below the 52-week high.
Oct 12, 2026 — BIIB rises 1.6% to $229.41, a 52-week high
- Closed at $229.41, +1.64% vs the prior close of $225.71. Day range $229.00–$238.24, opened at $233.98.
- Volume was 1.46M shares, 1.6x its 50-day average of 928.14K.
- Price is +5.4% vs its 50-day average ($217.58) and +16.6% vs its 200-day average ($196.71).
- 52-week range $138.00–$238.24; today's close sits at 91% of that range, 3.7% below the 52-week high.
Oct 9, 2026 — BIIB jumps 3.3% to $225.71
- Closed at $225.71, +3.33% vs the prior close of $218.43. Day range $219.23–$227.20, opened at $220.62.
- Volume was 815.00K shares, 0.9x its 50-day average of 929.70K.
- Price is +4.0% vs its 50-day average ($217.05) and +14.9% vs its 200-day average ($196.44).
- 52-week range $138.00–$230.49; today's close sits at 95% of that range, 2.1% below the 52-week high.
Oct 8, 2026 — BIIB dips 1.7% to $218.43, 3 down days in a row
- Closed at $218.43, -1.67% vs the prior close of $222.15. Day range $215.73–$223.09, opened at $220.15.
- Volume was 1.34M shares, 1.4x its 50-day average of 950.92K.
- Price is +0.8% vs its 50-day average ($216.69) and +11.3% vs its 200-day average ($196.19).
- 52-week range $138.00–$230.49; today's close sits at 87% of that range, 5.2% below the 52-week high.
- That makes 3 straight losses.
Oct 7, 2026 — BIIB dips 0.3% to $222.15
- Closed at $222.15, -0.33% vs the prior close of $222.89. Day range $221.40–$228.00, opened at $222.93.
- Volume was 1.30M shares, 1.3x its 50-day average of 961.60K.
- Price is +2.6% vs its 50-day average ($216.51) and +13.4% vs its 200-day average ($195.97).
- 52-week range $138.00–$230.49; today's close sits at 91% of that range, 3.6% below the 52-week high.
Oct 6, 2026 — BIIB dips 0.3% to $222.89
- Closed at $222.89, -0.31% vs the prior close of $223.59. Day range $218.00–$225.97, opened at $224.53.
- Volume was 1.01M shares, 1.1x its 50-day average of 956.69K.
- Price is +3.1% vs its 50-day average ($216.18) and +13.9% vs its 200-day average ($195.71).
- 52-week range $138.00–$230.49; today's close sits at 92% of that range, 3.3% below the 52-week high.
Oct 5, 2026 — BIIB rises 1.7% to $223.59
- Closed at $223.59, +1.69% vs the prior close of $219.88. Day range $218.22–$223.85, opened at $219.90.
- Volume was 951.30K shares, 1.0x its 50-day average of 949.59K.
- Price is +3.6% vs its 50-day average ($215.72) and +14.4% vs its 200-day average ($195.45).
- 52-week range $138.00–$230.49; today's close sits at 93% of that range, 3.0% below the 52-week high.
Oct 2, 2026 — BIIB dips 1.3% to $219.88, 4 down days in a row
- Closed at $219.88, -1.32% vs the prior close of $222.82. Day range $219.81–$224.08, opened at $222.98.
- Volume was 779.90K shares, 0.8x its 50-day average of 954.63K.
- Price is +2.1% vs its 50-day average ($215.29) and +12.6% vs its 200-day average ($195.19).
- 52-week range $138.00–$230.49; today's close sits at 89% of that range, 4.6% below the 52-week high.
- That makes 4 straight losses.
BIIB latest news & SEC filings
Every SEC filing by or about BIIB in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 5, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Godbout Sean converted options/RSUs into 27 shares on Oct 2, 2026; now holds 1,467
- Godbout Sean had withheld for taxes 8 shares at $219.88 (≈$1.76K) on Oct 2, 2026; now holds 1,459
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 3, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 12, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Aug 6, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 5, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Minor Lloyd sold 593 shares at $200.96 (≈$119.17K) on Aug 4, 2026
- Minor Lloyd sold 593 shares at $200.96 (≈$119.17K) on Aug 4, 2026
- Minor Lloyd sold 593 shares at $200.96 (≈$119.17K) on Aug 4, 2026
- Minor Lloyd sold 593 shares at $200.96 (≈$119.17K) on Aug 4, 2026
- Minor Lloyd sold 593 shares at $203.34 (≈$120.58K) on Aug 3, 2026
- Minor Lloyd sold 593 shares at $203.34 (≈$120.58K) on Aug 3, 2026
- …plus 2 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 4, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 3, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Jul 29, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Key figures from this report aren't in the SEC's structured data yet (usually appears within a day or two).
Jul 29, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 1, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Things to know before you trade BIIB
- Last results release: Jul 29, 2026 (8-K Item 2.02). Previous ones: Jul 1, 2026, Apr 29, 2026, Apr 6, 2026. Based on that rhythm, the next report is likely around Oct 28, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.20% (largest 3.3%).
- Liquidity: about 1.25M shares (≈$290.97M) trade per day on average.
- 52-week position: $232.65 vs a range of $138.00–$240.99 (92% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 4 open-market buys, 16 sales; latest: Lloyd Minor sold 593 shares on Aug 4, 2026.
- Latest filings: 10-Q Jul 29, 2026; 8-K Jul 29, 2026; 8-K Jul 1, 2026.
- Share count: 147.64M shares outstanding (Apr 27, 2026), +0.8% vs a year earlier.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
BIIB market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 235.77 | 236.74 | 232.46 | 232.65 | 1.46M |
| Oct 15, 2026 | 236.46 | 240.99 | 235.22 | 235.35 | 1.57M |
| Oct 14, 2026 | 228.99 | 234.20 | 228.00 | 232.83 | 1.95M |
| Oct 13, 2026 | 230.34 | 231.04 | 226.71 | 228.90 | 1.05M |
| Oct 12, 2026 | 233.98 | 238.24 | 229.00 | 229.41 | 1.46M |
| Oct 9, 2026 | 220.62 | 227.20 | 219.23 | 225.71 | 815.00K |
| Oct 8, 2026 | 220.15 | 223.09 | 215.73 | 218.43 | 1.34M |
| Oct 7, 2026 | 222.93 | 228.00 | 221.40 | 222.15 | 1.30M |
| Oct 6, 2026 | 224.53 | 225.97 | 218.00 | 222.89 | 1.01M |
| Oct 5, 2026 | 219.90 | 223.85 | 218.22 | 223.59 | 951.30K |
| Oct 2, 2026 | 222.98 | 224.08 | 219.81 | 219.88 | 779.90K |
| Oct 1, 2026 | 225.50 | 228.31 | 222.50 | 222.82 | 1.76M |
| Sep 30, 2026 | 227.23 | 229.36 | 225.51 | 225.88 | 1.55M |
| Sep 29, 2026 | 227.02 | 229.41 | 224.45 | 227.07 | 1.16M |
| Sep 28, 2026 | 225.87 | 230.49 | 225.51 | 228.69 | 1.33M |
| Sep 25, 2026 | 228.27 | 228.92 | 223.76 | 227.60 | 958.00K |
| Sep 24, 2026 | 226.80 | 228.72 | 224.31 | 226.36 | 1.03M |
| Sep 23, 2026 | 226.94 | 229.19 | 222.36 | 227.53 | 1.49M |
| Sep 22, 2026 | 219.22 | 226.43 | 219.00 | 225.36 | 1.11M |
| Sep 21, 2026 | 216.14 | 221.92 | 214.59 | 219.07 | 928.50K |
About Biogen
Biogen (BIIB) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in CAMBRIDGE, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 875045.
BIIB board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Maria C Freire | Director | Jun 11, 2026 |
| William A Hawkins | Director | Jun 11, 2026 |
| Susan Langer | Director | Jun 11, 2026 |
| Jesus B Mantas | Director | Jun 11, 2026 |
| Lloyd Minor | Director | Aug 5, 2026 |
| Menelas N Pangalos | Director | Jun 11, 2026 |
| Monish D Patolawala | Director | Jun 11, 2026 |
| Eric K Rowinsky | Director | Jun 11, 2026 |
| Stephen A Sherwin | Director | Jun 11, 2026 |
| Christopher Viehbacher | President and CEO | Feb 17, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Susan H Alexander | EVP Chief Legal Officer | Feb 17, 2026 |
| Sean Godbout | Chief Accounting Officer | Apr 3, 2026 |
| Ginger Gregory | EVP, Human Resources | Feb 17, 2026 |
| Jane Grogan | Head of Research | Feb 17, 2026 |
| Rachid Izzar | Head of Global Product Strat. | Feb 17, 2026 |
| Adam Keeney | Head of Corporate Development | May 5, 2026 |
| Robin Kramer | Chief Financial Officer | Feb 17, 2026 |
| Nicole Murphy | Head of Pharm Ops and Tech | Feb 17, 2026 |
| Michael Parini | Chief Legal Officer | Sep 3, 2026 |
| Priya Singhal | Head of Development | Feb 17, 2026 |
| Christopher Viehbacher | President and CEO | Feb 17, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 4, 2026 | Lloyd Minor | Sale | 593 | $200.96 |
| Aug 4, 2026 | Lloyd Minor | Sale | 593 | $200.96 |
| Aug 4, 2026 | Lloyd Minor | Sale | 593 | $200.96 |
| Aug 4, 2026 | Lloyd Minor | Sale | 593 | $200.96 |
| Aug 3, 2026 | Lloyd Minor | Sale | 593 | $203.34 |
| Aug 3, 2026 | Lloyd Minor | Sale | 593 | $203.34 |
| Aug 3, 2026 | Lloyd Minor | Sale | 593 | $203.34 |
| Aug 3, 2026 | Lloyd Minor | Sale | 593 | $203.34 |
| Feb 12, 2026 | Nicole Murphy | Buy | 3 | $195.04 |
| Feb 12, 2026 | Nicole Murphy | Buy | 3 | $195.04 |
| Feb 12, 2026 | Nicole Murphy | Buy | 3 | $195.04 |
| Feb 12, 2026 | Nicole Murphy | Buy | 3 | $195.04 |
| Feb 9, 2026 | Priya Singhal | Sale | 2,660 | $199.83 |
| Feb 9, 2026 | Priya Singhal | Sale | 2,660 | $199.83 |
| Feb 9, 2026 | Priya Singhal | Sale | 2,660 | $199.83 |
BIIB financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $9.89B | $1.29B | 8.79 | $2.20B |
| Dec 31, 2024 | $9.68B | $1.63B | 11.18 | $2.88B |
| Dec 31, 2023 | $9.84B | $1.16B | 7.97 | $1.55B |
| Dec 31, 2022 | $10.17B | $3.05B | 20.87 | $1.38B |
| Dec 31, 2021 | $10.98B | $1.56B | 10.40 | $3.64B |
Latest balance sheet: total assets $29.48B, total liabilities $10.83B, cash $2.91B (as of Mar 31, 2026).
BIIB earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Jul 29, 2026 | 8-K Item 2.02 (results) | $209.23 |
| Jul 1, 2026 | 8-K Item 2.02 (results) | $209.74 |
| Apr 29, 2026 | 8-K Item 2.02 (results) | $194.38 |
| Apr 6, 2026 | 8-K Item 2.02 (results) | $172.34 |
| Feb 6, 2026 | 8-K Item 2.02 (results) | $201.18 |
| Jan 14, 2026 | 8-K Item 2.02 (results) | $169.31 |
| Oct 30, 2025 | 8-K Item 2.02 (results) | $149.61 |
| Oct 14, 2025 | 8-K Item 2.02 (results) | $145.31 |
| Jul 31, 2025 | 8-K Item 2.02 (results) | $128.00 |
| Jul 7, 2025 | 8-K Item 2.02 (results) | $130.13 |
| May 1, 2025 | 8-K Item 2.02 (results) | $120.93 |
| Feb 12, 2025 | 8-K Item 2.02 (results) | $133.43 |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Revolution Medicines (RVMD)Argenx Se (ARGX)Kodiak Sciences (KOD)Greenland Mines (GRML)Halozyme Therapeutics (HALO)Repligen (RGEN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on BIIB
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.